La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

MicroPort CardioFlow Medtech Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jeffrey R Lindstrom

Amministratore delegato

CN¥4.0m

Compenso totale

Percentuale dello stipendio del CEO	59.8%
Mandato del CEO	1.1yrs
Proprietà del CEO	n/a
Durata media del management	3.9yrs
Durata media del Consiglio di amministrazione	3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jeffrey R Lindstrom rispetto agli utili di MicroPort CardioFlow Medtech?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CN¥349m
Mar 31 2024	n/a	n/a	-CN¥410m
Dec 31 2023	CN¥4m	CN¥2m	-CN¥472m

Compensazione vs Mercato: La retribuzione totale di Jeffrey R ($USD 570.00K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 809.04K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Jeffrey R con le performance aziendali.

AMMINISTRATORE DELEGATO

Jeffrey R Lindstrom (57 yo)

1.1yrs

Mandato

CN¥4,004,000

Compensazione

Mr. Jeffrey R Lindstrom is President, Executive Director & General Manager of MicroPort CardioFlow Medtech Corporation from August 29, 2023. He served as senior director of engineering in Edwards Lifescien...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeffrey R Lindstrom	President	1.1yrs	CN¥4.00m	Nessun dato
Liang Zhao	Executive Director & First VP of Total Solutions	2.3yrs	CN¥3.91m	0.058% CN¥ 134.9k
Luying Yan	VP & Executive Director	4yrs	CN¥2.70m	0.042% CN¥ 96.8k
Xiangmei Li	Joint Company Secretary	3.9yrs	Nessun dato	Nessun dato
Lok Yee Chan	Joint Company Secretary	3.9yrs	Nessun dato	Nessun dato

3.9yrs

Durata media

43yo

Età media

Gestione esperta: Il team dirigenziale di 72X è considerato esperto (durata media dell'incarico 3.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeffrey R Lindstrom	President	1.1yrs	CN¥4.00m	Nessun dato
Liang Zhao	Executive Director & First VP of Total Solutions	2.3yrs	CN¥3.91m	0.058% CN¥ 134.9k
Luying Yan	VP & Executive Director	4yrs	CN¥2.70m	0.042% CN¥ 96.8k
Jonathan H. Chou	Independent Non-Executive Director	3.7yrs	CN¥254.00k	Nessun dato
Xia Wu	Non-Executive Director	5.1yrs	Nessun dato	Nessun dato
Guoming Chen	Non-Executive Chairman of the Board	4yrs	CN¥3.16m	0.031% CN¥ 71.1k
Junjie Zhang	Non-Executive Director	5.1yrs	Nessun dato	Nessun dato
Zhixiang Sun	Independent Non-Executive Director	3.7yrs	CN¥254.00k	Nessun dato
Jiandong Ding	Independent Non-Executive Director	3.1yrs	CN¥254.00k	0.0012% CN¥ 2.9k

3.7yrs

Durata media

47yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 72X sono considerati esperti (durata media dell'incarico 3.6 anni).

MicroPort CardioFlow Medtech Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Recent updates

Now 28% undervalued

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.076 loss in 1H 2023)

Now 56% undervalued after recent price drop

MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024

Now 48% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

Forecast to breakeven in 2026

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC System

MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in Europe

MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI Product

First half 2023 earnings released: CN¥0.076 loss per share (vs CN¥0.052 loss in 1H 2022)

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Full year 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.079 loss in FY 2021)

Less than half of directors are independent

Microport Cardioflow Medtech Corporation Announces Registration in Colombia for Alwide Plus Balloon Catheter

First half 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.031 loss in 1H 2021)

MicroPort CardioFlow Medtech Corporation to Report Q2, 2022 Results on Aug 29, 2022

MicroPort CardioFlow Medtech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Microport Cardioflow Medtech Corporation Announces That the Transcatheter Mitral Valve Replacement System Independently Developed by the Group Was Successfully Applied by the Heart Team of Zhongshan Hospital

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

Full year 2021 earnings released: CN¥0.079 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.08 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

Microport Cardioflow Medtech Corporation Successfully Registered Vitaflow Liberty Transcatheter Aortic Valve Implantation System in Argentina

Microport Cardioflow Medtech Corporation Announces Ce Mark Registration Application for Vitaflow Libertytm

No longer forecast to breakeven

Forecast to breakeven in 2023

Independent Non-Executive Director Hualiang Jiang has left the company

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media